These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29381935)

  • 1. Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer.
    Hisakane K; Yoh K; Nakamura N; Udagawa H; Kirita K; Umemura S; Matsumoto S; Niho S; Akimoto T; Tsuboi M; Goto K
    Medicine (Baltimore); 2017 Nov; 96(47):e8635. PubMed ID: 29381935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Naito Y; Kubota K; Nihei K; Fujii T; Yoh K; Niho S; Goto K; Ohmatsu H; Saijo N; Nishiwaki Y
    J Thorac Oncol; 2008 Jun; 3(6):617-22. PubMed ID: 18520801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
    Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
    Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
    Shukuya T; Takahashi T; Tamiya A; Ono A; Igawa S; Tsuya A; Nakamura Y; Murakami H; Naito T; Kaira K; Endo M; Yamamoto N
    Jpn J Clin Oncol; 2009 Mar; 39(3):158-62. PubMed ID: 19139038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study.
    Oshiro Y; Okumura T; Kurishima K; Homma S; Mizumoto M; Ishikawa H; Onizuka M; Sakai M; Goto Y; Hizawa N; Sato Y; Sakurai H
    J Radiat Res; 2014 Sep; 55(5):959-65. PubMed ID: 24864278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.
    Horinouchi H; Sekine I; Sumi M; Noda K; Goto K; Mori K; Tamura T
    Cancer Sci; 2013 Jan; 104(1):93-7. PubMed ID: 23004347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
    Shukuya T; Takahashi T; Harada H; Akamatsu H; Sakaguchi C; Imai H; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi K; Yamamoto N
    Anticancer Res; 2012 Feb; 32(2):675-80. PubMed ID: 22287762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
    Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
    Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V
    Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer.
    Imamura F; Konishi K; Uchida J; Nishino K; Okuyama T; Kumagai T; Kawaguchi Y; Nishiyama K
    Clin Lung Cancer; 2014 Jul; 15(4):281-6. PubMed ID: 24656641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Zhao Q; Wang Z; Huang W; Wang Q; Yu S; Zhou T; Han D; Wu Z; Gong H; Sun H; Zhang J; Wei Y; Li H; Zhang Z; Lin H; Li B
    Oncotarget; 2016 Feb; 7(7):8422-31. PubMed ID: 26761213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.
    Kenmotsu H; Ohde Y; Shukuya T; Eida H; Akamatsu H; Ono A; Nakamura Y; Tsuya A; Kaira K; Naito T; Murakami H; Takahashi T; Maniwa T; Isaka M; Endo M; Kondo H; Yamamoto N
    Respir Investig; 2012 Dec; 50(4):157-61. PubMed ID: 23199980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
    Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M
    Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.